Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Change in Accured Expenses (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Change in Accured Expenses for 7 consecutive years, with $23.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Accured Expenses rose 366.29% year-over-year to $23.7 million, compared with a TTM value of $90.7 million through Dec 2025, up 265.01%, and an annual FY2025 reading of $90.7 million, up 265.01% over the prior year.
  • Change in Accured Expenses was $23.7 million for Q4 2025 at Avidity Biosciences, down from $52.2 million in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $52.2 million in Q3 2025 and bottomed at -$15.3 million in Q1 2025.
  • Average Change in Accured Expenses over 5 years is $6.2 million, with a median of $2.3 million recorded in 2021.
  • The sharpest move saw Change in Accured Expenses tumbled 888.42% in 2024, then skyrocketed 837.61% in 2025.
  • Year by year, Change in Accured Expenses stood at $2.2 million in 2021, then tumbled by 549.77% to -$9.8 million in 2022, then skyrocketed by 107.84% to $767000.0 in 2023, then surged by 562.97% to $5.1 million in 2024, then surged by 366.29% to $23.7 million in 2025.
  • Business Quant data shows Change in Accured Expenses for RNA at $23.7 million in Q4 2025, $52.2 million in Q3 2025, and $30.1 million in Q2 2025.